Compare · LNSR vs WST
LNSR vs WST
Side-by-side comparison of LENSAR Inc. (LNSR) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LNSR and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $24.89B, about 352.5x LNSR ($70.6M).
- Over the past year, LNSR is down 56.5% and WST is up 67.8% - WST leads by 124.3 points.
- WST has hit the wire 5 times in the past 4 weeks while LNSR has been quiet.
- WST has more recent analyst coverage (18 ratings vs 3 for LNSR).
- Company
- LENSAR Inc.
- West Pharmaceutical Services Inc.
- Price
- $5.75+1.23%
- $352.54-1.57%
- Market cap
- $70.6M
- $24.89B
- 1M return
- -8.22%
- +9.06%
- 1Y return
- -56.51%
- +67.76%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 5
- Recent ratings
- 3
- 18
LENSAR Inc.
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing an advanced femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. The company was incorporated in 2004 and is headquartered in Orlando, Florida.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest LNSR
- SEC Form DEFA14A filed by LENSAR Inc.
- SEC Form DEF 14A filed by LENSAR Inc.
- Director Hammer Todd B was granted 17,421 shares, increasing direct ownership by 45% to 56,083 units (SEC Form 4)
- Director Ellis Thomas B was granted 17,421 shares, increasing direct ownership by 45% to 56,083 units (SEC Form 4)
- Principal Accounting Officer Wong Kendra was granted 13,066 shares, increasing direct ownership by 30% to 56,481 units (SEC Form 4)
- Chief Operating Officer Connaughton Alan B. was granted 34,843 shares, increasing direct ownership by 10% to 389,173 units (SEC Form 4)
- Chief Executive Officer Curtis Nicholas T was granted 130,662 shares, increasing direct ownership by 13% to 1,122,758 units (SEC Form 4)
- Director Weisner Aimee S was granted 17,421 shares, increasing direct ownership by 19% to 110,368 units (SEC Form 4)
- Director O'Farrell Elizabeth G. was granted 17,421 shares, increasing direct ownership by 35% to 67,368 units (SEC Form 4)
- Director Winer Gary M was granted 17,421 shares, increasing direct ownership by 20% to 105,635 units (SEC Form 4)
Latest WST
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- BNP Paribas Exane initiated coverage on West Pharm with a new price target
- West to Host Second-Quarter 2026 Conference Call
- SEC Form 4 filed by Director Haugen Janet Brutschea
- West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System
- West Pharm upgraded by Barclays with a new price target
- Wolfe Research resumed coverage on West Pharm with a new price target
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- West Appoints Michel Lagarde to be President and Chief Executive Officer
- Amendment: West Pharmaceutical Services Inc. filed SEC Form 8-K: Financial Statements and Exhibits